GLUCOCORTICOID EFFECTS ON GROWTH IN INFANTS WITH HEMANGIOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项前瞻性、观察性队列研究，旨在评估接受高剂量糖皮质激素治疗的血管瘤婴儿是否会在伴有或不伴有骨矿物质增生减少的情况下损害体格生长。结果变量包括身高、体重、头围、年化身高速度和腰椎骨密度的变化。计划招募12名接受糖皮质激素治疗的血管瘤婴儿。他们将与未接受糖皮质激素治疗的对照血管瘤患者进行比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective, observational cohort study to evaluate if infants with hemangioma treated with high-dose glucocorticoids will have impaired statural growth with or without decreased bone mineral accretion. The outcome variables will be changes in height, weight, head circumference, annualized height velocity and changes in lumbar spine bone mineral density. Plan is to enroll 12 infants with hemangioma treated with glucocorticoids. They will be compared with control hemangioma patients not treated with glucocorticoids.